ResearcherSichuan UniversityActive in the last 2 years

Xingchen Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7042-718X; OpenAlex author ID A5051630281. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 4)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 4

Biomimetic Nanoplatform for Fibrosis Remodeling and Anti-PD-1 Potentiation via Cu+/Ca2+ Ion Dysregulation and TGF-β Inhibition in PDAC. Last author DOI 10.1002/advs.78436 ↗
Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer? Last author DOI 10.1111/apt.17537 ↗
Association between inflammatory bowel disease and pancreatic cancer: results from the two-sample Mendelian randomization study. Last author DOI 10.3389/fonc.2023.1155123 ↗
GLI1 expression in pancreatic ductal adenocarcinoma correlates the clinical significance and prognosis: A meta-analysis. Last author DOI 10.1097/md.0000000000020950 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Min Yu · 2 shared papers, 2023 · strength 0.50
- Paper Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer? DOI 10.1111/apt.17537 ↗
- Paper Association between inflammatory bowel disease and pancreatic cancer: results from the two-sample Mendelian randomizati… DOI 10.3389/fonc.2023.1155123 ↗
Jianmei Li · 1 shared paper, 2026 · strength 0.33
- Paper Biomimetic Nanoplatform for Fibrosis Remodeling and Anti-PD-1 Potentiation via Cu+/Ca2+ Ion Dysregulation and TGF-β Inh… DOI 10.1002/advs.78436 ↗
Ruidan Li · 1 shared paper, 2020 · strength 0.15
- Paper GLI1 expression in pancreatic ductal adenocarcinoma correlates the clinical significance and prognosis: A meta-analysis. DOI 10.1097/md.0000000000020950 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.